OLFML3 and colorectal carcinoma: Therefore, we also monitored the effect of tumor treatment with anti-OLFML3 antibodies on the expression of human and mouse angiogenesis-associated transcripts in human DLD1 CRC tumors treated with rec9F8, or bevacizumab.